Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PICALM interacting mitotic regulator (PIMREG)
- Target
- PIMREG
- Molecular classification
- Other (cell cycle regulator, mitotic regulator; not a classic enzyme, receptor, transporter, or transcription factor)
01
Overview
PIMREG (PICALM interacting mitotic regulator) is a nuclear protein encoded on chromosome 17 in humans, involved in cell cycle regulation, particularly the transition from metaphase to anaphase. It interacts with PICALM and HDAC2, participates in chromosomal segregation, and activates mitogenic signaling pathways such as β-catenin, NF-κB, and STAT3. Overexpression of PIMREG promotes tumor cell proliferation, migration, and invasion, and high levels are linked to poor cancer prognosis. Inhibiting β-catenin signaling with agents such as ICG-001 can impede its oncogenic effects in vitro, establishing it as a potential therapeutic target in oncology, especially for gliomas and other aggressive cancers.
- Other names
- FAM64ACATSRCS1Regulator of chromosome segregation protein 1CALM-interactor expressed in thymus and spleenCALM interacting protein expressed in thymus and spleen
02
Mechanism of action
Inhibition of β-catenin signaling blocks tumor-promoting function of PIMREG
03
Biological functions
Cell cycle progression (promotes metaphase-to-anaphase transition; marker of proliferation)Cell proliferationTumor promotion (by enhancing migration and invasion)Activation of β-catenin signaling pathwayModulation of NF-κB and STAT3 signaling (especially in cancer and inflammation)
04
Disease associations
Cancer (glioma, breast cancer, cholangiocarcinoma, pancreatic cancer, osteosarcoma)Inflammation-associated cancer (via STAT3 signaling)Potential roles in cell cycle diseases and developmental disorders
05
Safety considerations
Therapeutic targeting could affect normal cell proliferation and cell cycle progression, risking off-target toxicity and cytopenias due to its role as a general proliferation marker
06
Interacting drugs
ICG-001
07
Biomarkers
Marker of proliferation in normal and malignant cellsHigh expression associated with poor prognosis in several cancers
Beyond the preview
Go deeper on PICALM interacting mitotic regulator (PIMREG).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PICALM interacting mitotic regulator (PIMREG).